In summary, the present study revealed the underlying mechanism by which darolutamide induces ferroptosis through the SREBP1-FASN axis in PCa, suggesting that the combination of darolutamide with FINs could be a promising therapeutic strategy for PCa patients with AR mutations. Here, AR is linked to posterior cortical atrophy.